MGMT and glioblastoma: Finally, Checkmate 548 was a randomized phase 3 study testing the addition of nivolumab to standard chemoradiotherapy in MGMT methylated glioblastoma, and similarly showed no improvements in OS (Weller et al, manuscript submitted).